Reducing Inappropriate Utilization of Albumin: The Value of Pharmacist-led Intervention Model

Document Type: Research article

Authors

1 Pharmacovigilance Department, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. .

2 Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Chronic Respiratory Diseases Research Center (CRDRC), NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Chronic Respiratory Diseases Research Center (CRDRC), NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences ,Tehran, Iran

6 Pharmacovigilance Department, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

7 harmacovigilance Department, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

8 School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Albumin is known as a human blood product, with high cost and limited availability. Several studies have demonstrated the extent in which albumin is being utilized in controversial indications not supported or weakly supported by the available literature.
Objective: To rationalize the use of albumin and to decrease the inappropriate cost of this expensive drug.
Methods: A two phase study, with equal length of 66-days, comprising an observational drug utilization evaluation and a pharmacist-led audit and feedback interventional study, was conducted in a tertiary referral hospital in Tehran, Iran. The results of the interventional phase including the introduction of evidence-base guideline for albumin via a pharmacist-led audit and feedback intervention was compared to the ones from the observational phase.
Results: A total of 90 and 45 patients were included in the phase one and phase two of the study respectively. During the initial phase, 1870 albumin vials were used, of which 1467 (78.4%) vials were prescribed inappropriately. Inappropriate use of albumin was decreased significantly by 79.3% (p <0.001) through the interventional phase, leading to 38,800 USD reduction in inappropriate costs of albumin.
Conclusion: Introduction of evidence based guideline in conjugation with pharmacist-led audit and feedback can significantly decrease the inappropriate use of albumin. These results also demonstrate shifting towards a more evidence-based practice, which can increase patient’s safety and enhance quality of care.

Keywords

Main Subjects